ARA Avanti Rx Analytics



May 10, 2017

Delivra Signs Exclusive Licensing Deal with ARA-Avanti Rx Analytics for Hemp Non-Psychoactive Cannabinoid, Terpene and Flavonoid Formulations and Products

TORONTO, ON--(Marketwired - May 10, 2017) - Delivra Corp. (TSX VENTURE: DVA) ("Delivra" or the "Company") and ARA-Avanti Rx Analytics Inc. ("Avanti") announced today a strategic partnership to develop a unique suite of standardized natural and medicinal products for the medical pain-related research, development, and commercialization markets, using hemp.

The hemp plant has been hugely overlooked as a great alternative for pain management and other medical conditions. The partnership between the two companies addresses many of the concerns of the unsettling psychotropic effects of THC found in cannabis, especially in the elderly and high anxiety patient population. In comparison, hemp contains low THC cannabis content and many beneficial cannabinoids, including cannabidiol (CBD). Hemp is also known for its diverse and robust anti-inflammatory flavonoids content, along with its high nutritional value because of its high essential polyunsaturated fatty acids (omega 3's), which matches that of the human body. Properly administered, medical non-psychotropic cannabis provides real alternatives to more addictive type drugs, including opioids........Read More


April 20, 2017

Canadian company working on topical cream containing medical marijuana

Canadian medical marijuana patients could soon find themselves ditching the pipe, bong or vaporizer for a topical cream or an oral spray that contains the active ingredients of cannabis, according to the CEO of biotechnology company Delivra Corp. .......Read More


April 19, 2017

Algae Dynamics Corp Announces Joint Venture with ARA - Avanti Rx Analytics Inc. to Formulate, Manufacture and Sell Products Utilizing Algae, Hemp & Cannabis Oils

TORONTO, ON--April 19, 2017 ALGAE DYNAMICS CORP (OTCQB: ADYNF) (the "Company" or “ADC”), a company focused on the development of unique health products and pharmaceuticals utilizing cannabis, hemp and algae oils today announced a joint venture with ARA - Avanti Rx Analytics Inc. (“ARA”) in a newly-formed subsidiary entity called ADC Biomedical Corp (“BIO”), the equity of which will be owned 4% and 96% by ARA and ADC, respectively. Previously, the Company had announced a memorandum of understanding with ARA with respect to strategic collaboration between the two companies. This announcement is an extension of that previously-announced collaboration.

It is the intention of the joint venture for BIO to be the preferred purchaser from ARA of all BIO’s and ADC’s products containing algae, hemp oil, and cannabis extracted oils, and/or their compounds. ADC will be responsible for the provision of raw materials, or if required by law, will arrange for the provision of raw materials to ARA for processing. ARA will be responsible for processing the raw materials into finished bulk goods and/or packaged products, and shipping same to BIO’s licensed clients/sellers and research organizations. ARA will process materials according to agreed prices and specifications, which may be modified from time to time. The initial term of the joint venture is for three (3) years, effective April 10, 2017, renewing automatically unless notice is given from one party to the other to terminate. In addition, the joint venture may be terminated upon the occurrence of a material breach that remains uncured for 60 days.” .......Read More


April 18, 2017

ICC Enters into Importation Agreement with ARA – Avanti Rx Analytics

Vancouver, British Columbia, Tuesday, April 18, 2017 - ICC International Cannabis Corporation (“ICC” or the “Company”) (TSXV: ICC) is pleased to announce that it has entered into an Importation Agreement with ARA – Avanti Rx Analytics Inc. (“Avanti”), a licensed dealer under the Controlled Drugs and Substances Act (Canada) and its regulations overseen by Health Canada.

“We are pleased to enter into the Importation Agreement with Avanti with a view to working together to provide Canadians with a broader supply of cannabidiol (“CBD”) oil and cannabis extract oils, and other related products from our Uruguayan operations at competitive price points,” commented Guillermo Delmonte, Chief Executive Officer of ICC. “In addition, Avanti brings to the table extensive knowledge and expertise in the field of quality control, cannabis extraction, and CBD purification. The business relationship with Avanti is expected to allow ICC to leverage Avanti’s dealer license and laboratory facilities in order to facilitate sales in Canada, and represents a positive next step in ICC’s strategy to export to global markets where lawful.” .......Read More


April 12, 2017

Cura-Can Health Enters Into Services Agreement With ARA-Avanti Rx

TORONTO, ONTARIO--(Marketwired - April 12, 2017) - Cura-Can Health Corp.("Cura-Can" or the "Company") a private, federally incorporated company, is pleased to announce that its wholly-owned subsidiary, The Clinic Network Canada Inc. ("TCNC"), has entered into a services agreement with ARA-Avanti Rx Analytics Inc. (the "Avanti") pursuant to which Avanti has agreed to produce cannabidiol ("CBD") based products, for both medicinal and supplement applications, for sale by TCNC directly to medical patients and non-medical clients, through its Cura "SELECT" house brand (the "Services Agreement").

Avanti is a leading Health Canada approved contract organization specializing in the field of controlled drugs and substances particularly in the area of medicinal marihuana, hemp, cannabinoids, and marihuana based concentrated products. Avanti offers a comprehensive menu of services ranging from analytical research and development, and quality control testing, marihuana extraction, cannabinoid purification, cannabis infused-product formulation, and cannabis waste management, as well as quality assessment and regulatory consulting. .......Read More


March 21, 2017

Delivra Signs Exclusive Licensing Deal with Dosecann for Cannabis Oil Formulations in Metered Dose Formats

March 21, 2017 – Toronto, Ontario – Delivra Corp. (TSXV: DVA – “Delivra” or the “Company”), Dosecann Inc. (“Dosecann”) and ARA-Avanti Rx Analytics Inc. (“Avanti”) announced today a strategic partnership to develop a unique suite of standardized products for the medical cannabis research, development, and commercialization markets.

“The Federal Government of Canada has numerous concerns, and barriers to overcome, before legalizing cannabis, including stricter regulatory controls. The partnership between the three companies addresses many of these concerns, providing greater safety and efficacy of medical cannabis specific products for the patient, with products that provide consistent, accurate dosing, and that are manufactured under pharmaceutical GMP Standards,” said Dr. Joseph Gabriele, CEO of Delivra. “This collaboration between Delivra, Dosecann and Avanti addresses an exploding field of medicine by seeking to standardize, validate, package and distribute cannabis products in innovative mono-dose delivery platforms to licensed producers and other future legal distribution networks, ultimately meeting the needs of the patient.” .......Read More


March 16, 2017

Algae Dynamics Corp Announces Memorandum of Understanding with Company Licenced by Health Canada to Test, Extract, Purify, Import/ Export and Sell Cannabis Oil

TORONTO, CANADA / March 16, 2017, 9:30 AM EDT/ ALGAE DYNAMICS CORP (OTCQB: ADYNF)(the "Company" or “ADC”), a development stage company focused on the development of unique health products and pharmaceuticals utilizing cannabis and algae oils, today announced a memorandum of understanding with Avanti Rx Analytics Inc. (“ARA”) to collaborate on a range of topics as outlined below. ARA is uniquely positioned to test, extract, develop, produce and supply cannabinoids that can enable and enhance the delivery and commercial success of medicinal cannabis products. As such, ARA will play a key role in supplying the University of Waterloo and Western University with cannabis oil for the previously announced sponsored research programs, in addition to contributing to the product development and formulation opportunities that combine the benefits of algae and cannabis oils.

Paul Ramsay, Chairman and President of the Company said, “This collaboration is a vital piece of our corporate development strategy. Our relationship with ARA will assist us immensely in the development of unique products both in the medical cannabis category, as well as in unique formulations utilizing cannabis and algae oils. It dove-tails beautifully with our recently announced research relationships with two universities, and we believe will help fast-track us to revenue.” .......Read More


December 12, 2016

The Daily Marijuana Observer - Canada Licensed Dealers List

According to a Government of Canada website, the following is a list of laboratories that have a current Dealers License under the Narcotic Control Regulations and who are licensed to conduct special activities with cannabis. .......Read More


Elemental Impurities: new USP chapters <232>, <233>, and <2232>

Drug products and dietary supplements for the US market will soon have to comply with the new elemental impurities requirements and testing set forth by the USP General Chapters <232> Elemental Impurities—Limits, <233> Elemental Impurities—Procedures, and <2232> Elemental Contaminants in Dietary Supplements. The USP recognized that the current chapter <231> Heavy Metals was obsolete, and it will be eliminated completely on 1/1/2018, when also the new chapters will be officially implemented.

These new chapters include the use of modern procedures and analytical equipment, and establish the limits for acceptable levels of elemental impurities in drug products and dietary supplements. These changes will affect not just the drug manufacturers but also the raw materials supplier for active pharmaceutical ingredients (APIs) and/or excipients